RxDoctor Payments Data

Peter-Brian Andersson, MD

Neurology · Tarzana, CANPI 1326063843

Payments from drug & device makers

$97,440in general payments, 2019–2025

Across 1,193 payments — averaging $81.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$37K
  • Lilly USA, LLC$25K
  • Biohaven Pharmaceuticals, Inc.$12K
  • Impel Pharmaceuticals Inc.$4K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$1K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$3,9764%
  • Speaking & faculty fees$69,70072%
  • Grants$850%
  • Travel & lodging$1910%
  • Food & beverage$23,17424%
  • Education$3140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)127$37,270
Lilly USA, LLC54$25,399
Biohaven Pharmaceuticals, Inc.26$11,781
Impel Pharmaceuticals Inc.10$4,069
Teva Pharmaceuticals USA, Inc.71$1,409
Biogen69$1,340
Novartis83$1,295
Amgen(2 entities)52$934
Acadia Pharmaceuticals Inc45$825
Pfizer49$788
MDD US Operations, LLC64$769
SK Life Science, Inc.35$732
Eisai Inc.39$702
Neurocrine Biosciences, Inc.23$589
UCB, Inc.17$510
Lundbeck LLC20$457
Merz Pharmaceuticals, LLC14$426
Kyowa Kirin, Inc.19$418
AstraZeneca(2 entities)18$404
Argenx US, Inc.16$388
Axsome Therapeutics, Inc.18$372
Otsuka America Pharmaceutical, Inc.21$362
Sunovion Pharmaceuticals Inc.20$351
Amneal Pharmaceuticals LLC18$348
Genentech USA, Inc.13$334
Alnylam Pharmaceuticals Inc.17$327
EMD Serono, Inc.14$294
Sumitomo Pharma America, Inc.14$279
Takeda Pharmaceuticals U.S.A., Inc.12$263
Bristol Myers Squibb11$248
Acorda Therapeutics, Inc10$210
Biohaven Pharmaceutical Holding Company Ltd.11$204
Harmony Biosciences LLC7$200
Jazz Pharmaceuticals Inc.7$183
Adamas Pharmaceuticals, Inc.10$176
Azurity Pharmaceuticals, Inc.9$171
Catalyst Pharmaceuticals, Inc.8$164
TG Therapeutics, Inc.6$158
Assertio Therapeutics, Inc.7$138
Arbor Pharmaceuticals, Inc.8$138
Sanofi5$124
Neurelis, Inc.7$124
Banner Life Sciences, LLC7$122
Supernus Pharmaceuticals, Inc.8$114
Nevro Corp.4$113
Forte Bio-pharma LLC5$110
Abbott6$101
Upsher-smith Laboratories LLC4$99
Tanabe Pharma America, Inc.5$96
Cycle Pharmaceuticals Inc3$94
Tonix Medicines, Inc.4$83
Octapharma USA, Inc.3$82
CSL Behring3$77
Zyla Life Sciences, Inc.9$76
Vanda Pharmaceuticals Inc.3$64
Merz North America, Inc.3$60
Genentech, Inc.2$56
Promius Pharma LLC2$49
Bausch Health US, LLC2$44
Johnson & Johnson2$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,440 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$405,831
Medicare patients
828
Services billed
2,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone16$227,788
NuplazidPimavanserin Tartrate35$174,678
GocovriAmantadine Hcl48$161,957
Avonex Pen (4 Pack)Interferon Beta-1a16$131,923
Nurtec OdtRimegepant Sulfate66$87,273
Aimovig AutoinjectorErenumab-Aooe87$67,879
BriviactBrivaracetam22$49,861
FycompaPerampanel25$35,397
QuliptaAtogepant25$26,647
Emgality PenGalcanezumab-Gnlm31$26,319
Ajovy AutoinjectorFremanezumab-Vfrm28$23,416
OngentysOpicapone23$15,483
Carbidopa-LevodopaCarbidopa/Levodopa223$9,806
TrintellixVortioxetine Hydrobromide13$6,273
Pregabalin133$5,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$825$174,67835 claims
MDD US Operations, LLCGocovri$769$161,95748 claims
PfizerNurtec Odt, Dilantin$788$89,14177 claims
UCB, Inc.Briviact$510$49,86122 claims
Eisai Inc.Fycompa$702$35,39725 claims
AbbVieQulipta$37,270$26,64725 claims
Neurocrine Biosciences, Inc.Ongentys$589$15,48323 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$263$6,27313 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$348$96021 claims
Upsher-smith Laboratories LLCTopiramate$99$48122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →